大连美创药业

Dalian Meichuang Pharmaceutical is a Chinese pharmaceutical company dedicated to the research, development, and manufacturing of innovative chemical drugs and high-quality generics. Established in 2004 and based in the Dalian High-tech Zone, the company focuses on therapeutic areas including metabolic diseases, cardiovascular health, and anti-infectives. Its lead innovative asset, MC-001, is a small molecule URAT1 inhibitor currently in clinical trials for the treatment of hyperuricemia and gout. Meichuang operates integrated R&D centers and GMP-compliant production facilities for both active pharmaceutical ingredients (APIs) and finished dosage forms. The company aims to bridge the gap between drug discovery and commercialization to provide affordable therapeutic options for patients in China.